The most expensive drugs in the world — starting at the low price of $1 million: The majority of these drugs treat illness affecting less than 200,000 people
qz.com/most-expensive-drugs-2024-lenmeldy-hemgenix-elevidys-1851356958
Paid articlePaid
U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy: Sarepta Therapeutics said on Friday that the U.S. FDA will not conduct a meeting of ...
reut.rs/48lpFt2
Quick Glance: Ex-FBI Informant Charged with Lying about Joe Biden and Son
- The U.S. special counsel leading a criminal probe into President Joe Biden's son, Hunter Biden, charged a former FBI informant for lying about their alleged involvement in business dealings with Ukrainian energy company Burisma Holdings.
- A federal grand jury indicted Alexander Smirnov, 43, for making false statements and creating a false record in relation to an FBI probe.
- The indictment states that Smirnov falsely recounted meetings where Burisma executives claimed to have hired Hunter Biden to solve problems through his father.
- Smirnov falsely claimed that Burisma executives paid $5 million to Joe Biden and Hunter Biden for his son to address issues through his father during a criminal investigation.
Prospects Look Better for Sarepta Gene Therapy, Sending the Stock Up Again: Investors looking for signs the FDA will let more patients use Sarepta Therapeutics’ ...
on.barrons.com/42MlPbh
Paid articlePaid
Get expert insight on how to develop a transition of care plan for patients with spinal muscular atrophy moving from pediatric to adult care ... Show more ms.spr.ly/6188i7vL2
Sarepta Therapeutics: Leading The Way In DMD Treatment With Gene Therapy Innovations
seekingalpha.com/article/4664594-sarepta-therapeutics-leading-the-way-in-dmd-treatment-with-gene-therapy-innovations
Paid articlePaid
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
barrons.com/articles/sarepta-stock-rebounded-fda-dmd-b21876ed
Paid articlePaid
Sarepta's new Duchenne drug outperforms bestseller Exondys in trial: Sarepta Therapeutics (SRPT.O) said on Monday its new experimental drug for Duchenne muscular ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-says-its-experimental-duchenne-drug-more-effective-than-older-medicine-2024-01-29/
Sarepta defeats Regenxbio, UPenn patent lawsuit over muscular dystrophy treatment
reuters.com/legal/litigation/sarepta-defeats-regenxbio-upenn-patent-lawsuit-over-muscular-dystrophy-treatment-2024-01-05/
Sarepta's new Duchenne drug outperforms bestseller Exondys in trial: Sarepta Therapeutics (SRPT.O) said on Monday its new experimental drug for Duchenne muscular ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-says-its-experimental-duchenne-drug-more-effective-than-older-medicine-2024-01-29/
4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024: 4D Molecular Therapeutics (FDMT): Seveal catalysts/value inflection points in 2024 ...
seekingalpha.com/article/4664889-4d-molecular-therapeutics-several-value-inflection-points-to-watch-in-2024
Paid articlePaid
Dyne's shares jump after promising data on muscle disorder treatment: Shares of drug developer Dyne Therapeutics (DYN.O) jumped 18% on Wednesday after its ...
reuters.com/business/healthcare-pharmaceuticals/dynes-shares-surge-after-promising-data-muscle-disorder-treatment-2024-01-03/
Douglas S. Ingram, President and Chief Executive Officer of Sarepta Therapeutics, joined Alex Knapp to discuss innovation in detecting ... Show more #ForbesHealth on.forbes.com/6180Ryr9Q
Sarepta (SRPT) to Seek Approval for DMD Therapy Even After Drug Trial Failed: Normally when a drug fails to show a clear effect in a final-stage trial ...
bloomberg.com/news/articles/2023-10-31/after-drug-trial-fizzles-sarepta-still-seeks-broader-approval
Sarepta Crashes 45% After Its Gene Therapy Flops Its Biggest Test: Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey ...
investors.com/news/technology/srpt-stock-halted-after-sarepta-unveils-mixed-results-for-duchenne-gene-therapy/
These insiders were big buyers this week, including in one beaten-up biotech: CNBC Pro screened for the five U.S. companies with the biggest insider buying over ...
cnbc.com/2023/11/10/these-insiders-were-big-buyers-this-week-including-in-one-beaten-up-biotech.html
Paid articlePaid
Beware these companies due to report earnings that have negative profit momentum: Analysts have been cutting earnings estimates for these four stocks ahead of ...
cnbc.com/2023/11/09/beware-these-companies-due-to-report-but-that-have-negative-momentum.html
Paid articlePaid
Biotech Stocks Near An Inflection Point In Gene Therapy: The big names behind biotech stocks want to cure diseases, not just treat them. Gene therapy drugs are ...
investors.com/news/technology/biotech-stocks-near-a-significant-inflection-point-in-gene-therapy-but-watch-your-wallet/
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young children
pbs.org/newshour/health/first-gene-therapy-for-deadly-form-of-muscular-dystrophy-gets-fda-approval-for-young-kids
Quick Glance: FDA Approves Sarepta's Gene Therapy for Rare Muscular Dystrophy
- The US health regulator has granted accelerated approval to Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD).
- Initially seeking approval for DMD patients who can walk.
- Sarepta's gene therapy was able to produce a mini version of the dystrophin protein, but did not improve patient clinical outcomes.
- Approval for Sarepta's treatment could open doors for more effective gene therapies.
First Gene Therapy for Muscular Dystrophy Approved: The drug, from Sarepta Therapeutics, promises to repair the defective gene at the root of the fatal disorder ...
wsj.com/articles/first-gene-therapy-for-muscular-dystrophy-approved-34860988
Sarepta says FDA may limit gene therapy nod to smaller population, shares fall: Sarepta Therapeutics Inc (SRPT.O) said the U.S. drug regulator could initially ...
reuters.com/business/healthcare-pharmaceuticals/fda-defers-decision-sareptas-gene-therapy-june-22-2023-05-24/
FDA advisers narrowly back first gene therapy for muscular dystrophy: A panel of experts voted 8-6 in favor of Food and Drug Administration approval of the first ...
npr.org/sections/health-shots/2023/05/12/1175852294/fda-advisers-narrowly-back-first-gene-therapy-for-muscular-dystrophy
Sarepta surges after FDA panel backs Duchenne gene therapy: Shares of Sarepta Therapeutics (SRPT.O) jumped 25% on Monday as a backing by the U.S ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-surges-after-fda-panel-backs-duchenne-gene-therapy-2023-05-15/
Sarepta surges after FDA panel backs Duchenne gene therapy: Shares of Sarepta Therapeutics (SRPT.O) jumped 25% on Monday as a backing by the U.S ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-surges-after-fda-panel-backs-duchenne-gene-therapy-2023-05-15/
Drug Companies Are Minting Billions on Unproven Treatments With FDA Shortcut: Accelerated approvals have helped get promising therapies to market fast — but ...
bloomberg.com/news/articles/2023-05-14/fda-fast-tracked-drugs-make-companies-billions-on-unproven-claims
FDA advisers narrowly vote in favor of experimental gene therapy for rare muscle disease
cnn.com/2023/05/12/health/duchenne-muscular-dystrophy-therapy-fda/
Sarepta drops as report says FDA almost rejected under-review gene therapy: Sarepta Therapeutics Inc's shares (SRPT.O) fell more than 6% on Thursday as Stat News ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-shares-drop-report-says-fda-almost-rejected-under-review-gene-therapy-2023-04-13/
Gene therapy for muscular dystrophy stirs hopes and controversy: The FDA is considering greenlighting the experimental treatment under its accelerated approvals ...
npr.org/sections/health-shots/2023/05/02/1171357002/gene-therapy-for-muscular-dystrophy-stirs-hopes-and-controversy
Sarepta slides as FDA about-turn on panel clouds gene therapy approval path: Shares of Sarepta Therapeutics Inc (SRPT.O) slumped as much as 21% on Friday on ...
reuters.com/business/healthcare-pharmaceuticals/sarepta-slides-surprise-fda-panel-meeting-adds-uncertainty-gene-therapy-2023-03-17/
Here are Tuesday's biggest analyst calls: Apple, Amazon, Boeing, Chipotle, Rivian, Etsy, Exxon & more
cnbc.com/2023/04/04/tuesdays-top-wall-street-analyst-calls-include-xom-and-etsy.html
Paid articlePaid
Here are Wednesday's biggest analyst calls: Apple, Procter & Gamble, Tesla, Spotify, AbbVie & more
cnbc.com/2023/03/01/wall-streets-top-analyst-calls-on-wednesday-include-apple-spotify.html
Paid articlePaid
Citi says the recent sell-off in this biotech stock is 'overdone,' predicts shares can rally 30% from here
cnbc.com/2023/04/04/citi-says-the-recent-selloff-in-this-biotech-stock-is-overdone.html
Paid articlePaid
Sarepta Breaks Out As FDA Smooths The Path For Its Gene Therapy: Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy ...
investors.com/news/technology/srpt-stock-breaks-out-as-fda-smooths-the-path-for-its-gene-therapy/
ASX: $ANP 📓 An #Upcoming US #Study ? Internal Changes? ~ Updates & Insights With #MarkDiamond , CEO! #AntisenseTherapeutics is a #biotech co. developing & commercializing antisense ... Show more #pharmaceuticals #unmetmarkets #rarediseases www.antisense.com.au/ @AntisenseL #ad
Wall Street ends down sharply, hit by Apple and China worries: U.S. stocks ended sharply lower on Monday after protests in major Chinese cities against strict ...
reuters.com/markets/us/wall-st-futures-slip-china-covid-woes-apple-falls-2022-11-28/
Quick Glance: China's Deadly Fires Fuel Protests Against Xi's Covid Policies
- Travel restrictions and government restrictions on international journalists make it impossible to report on the protests.
- "We want freedom," they declared.
- For the most part, since Covid spread from Wuhan about three years ago, many Chinese have accepted severe regulations, including extensive travel restrictions, as a price for avoiding the widespread illness and death that the United States and other countries experienced.
- The Chinese authorities is likely to be concerned that photographs and footage of the Shanghai protests may spread over online control, inciting further upheaval.
Here are Thursday's biggest analyst calls: Apple, GameStop, First Solar, Boeing, Moderna & more
cnbc.com/2022/09/08/thursday-street-calls-apple-gamestop-first-solar-boeing-moderna-.html
Paid articlePaid
Ray Dalio on a buying spree - he bought these three stocks: Hedge fund manager legend Ray Dalio has been on a buying spree. But which stocks are particularly ...
boerse-online.de/nachrichten/aktien/ray-dalio-auf-einkaufstour-diese-drei-aktien-hat-er-gekauft-1031695286
Wall Street pros say these small caps are good buys as recession looms — BofA gives one 40% upside
cnbc.com/2022/08/03/wall-street-small-cap-stocks-that-could-outperform-in-a-recession.html
Paid articlePaid
Stocks making the biggest moves after hours: FedEx, Sarepta Therapeutics and more
cnbc.com/2022/06/23/stocks-moving-after-hours-fedex-sarepta-therapeutics-and-more.html
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics